Molecular Devices Introduces Two Assay Kits for Early ADME Screening
09 April 2005 - 7:48AM
PR Newswire (US)
Molecular Devices Introduces Two Assay Kits for Early ADME
Screening SUNNYVALE, Calif., April 8 /PRNewswire-FirstCall/ --
Molecular Devices Corporation (NASDAQ:MDCC) today announced the
introduction of two new reagent products for ADME assay
screening-Transil(R) Membrane Affinity and Transil Human Serum
Albumin (HSA) Binding assay kits. The Transil assay kits provide
lead optimization and high-throughput screening laboratories with
fast, automatable, direct, biologically relevant solutions to
increase the throughput of ADME-related compound profiling. The
Transil Membrane Affinity assay provides data that correlates
better to in vivo studies compared to the more conventional
water/octanol partitioning assays because it uses beads which are
coated with a lipid bilayer that mimic interactions between
compounds and cell membranes. The results are equivalent to the
liposome "gold standard" method, without the tedious preparation of
liposomes. The Transil HSA Binding assay kit makes routine,
high-throughput HSA binding characterization easy because it
contains beads which have been coated with human serum albumin and
pre-dispensed into a microplate format. The pre-dispensed format
increases throughput via parallel sample preparation and assay
reading on Molecular Devices' SpectraMax(R) microplate readers.
With the Transil assays, there is virtually no methods development
required, as each kit contains data analysis routines for
processing high- throughput screening of drug candidates for early
ADME characterization. Furthermore, the assays share nearly
identical sample workup steps, so steps developed for one assay are
immediately applicable to the other. Commenting on the launch,
Christopher Silva, Director of Marketing for Life Sciences Products
at Molecular Devices stated, "The Transil assay kits enable
screening of compound libraries for membrane affinity and HSA
binding for early ADME properties which are not possible with
current low-throughput methods. These new assays require only one
sample concentration, which simplifies automation. Additionally,
turnkey data analysis offers researchers compound data within hours
of synthesis or secondary screening. Because we have integrated
these assays with our SpectraMax(R) microplate reader line, we have
provided a more complete solution to our customers." The kits are
available in two formats for 96- or 384-well microplates. The "high
precision" version is ideal for profiling compounds at the lead
optimization stage of drug discovery; the "high throughput" version
allows characterization of compound libraries. Molecular Devices
Corporation is a leading supplier of high-performance bioanalytical
measurement systems that accelerate and improve drug discovery and
other life sciences research. The Company's systems and consumables
enable pharmaceutical and biotechnology companies to leverage
advances in genomics, proteomics and parallel chemistry to
facilitate the high-throughput and cost-effective identification
and evaluation of drug candidates. The Company's solutions are
based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry.
Molecular Devices enables its customers to improve research
productivity and effectiveness, which ultimately accelerates the
complex process of discovering and developing new drugs. This press
release contains "forward-looking" statements, including statements
related to the prospects for or potential customer use of the
Transil Membrane Affinity and Transil Human Serum Albumin (HSA)
Binding assay kits. Any statements contained in this press release
that are not statements of historical fact may be deemed to be
forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "will," and similar expressions
are intended to identify forward-looking statements. There are a
number of important factors that could cause the results of
Molecular Devices Corporation to differ materially from those
indicated by these forward-looking statements, including, among
others, risks related to the development of new products and other
risks detailed from time to time in the Company's SEC reports,
including its Annual Report on Form 10-K for the year ended
December 31, 2004. Molecular Devices Corporation does not undertake
any obligation to update forward-looking statements. DATASOURCE:
Molecular Devices Corporation CONTACT: Tim Harkness of Molecular
Devices Corporation, +1-408-747-3533 Web site:
http://www.moleculardevices.com/
Copyright
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Molecular Devices (MM) (NASDAQ): 0 recent articles
More Molecular Devices (MM) News Articles